All Stories

  1. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders
  2. Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses
  3. Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness
  4. Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution
  5. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition
  6. Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations
  7. The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction
  8. Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia
  9. Autoimmunity and psychosis
  10. Breast cancer in schizophrenia could be interleukin-33-mediated
  11. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview
  12. Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
  13. Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry—A European Survey
  14. Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment
  15. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia
  16. Peripheral Markers of Immune Response in Major Psychiatric Disorders: Where Are We Now and Where Do We Want to Be?
  17. The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Sumadia district of Serbia
  18. Еffects of Antipsychotics on Bone Mineral Density in Schizophrenia
  19. Oxidative stress and neuroinflammation should be both considered in the occurrence of fatigue and depression in multiple sclerosis
  20. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis
  21. Interplay of Brain-Derived Neurotrophic Factor and Cytokines in Schizophrenia
  22. POSITIVE IMPACT OF PRESCRIBED PHYSICAL ACTIVITY ON SYMPTOMS OF SCHIZOPHRENIA: RANDOMIZED CLINICAL TRIAL
  23. Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance?
  24. Cross-national Trainee Collaboration-The EFPT Research Experience in Psychiatry
  25. Elevated sera levels of galectin-3 in stable schizophrenia
  26. The EFPT-PSUD survey
  27. Quality of Life in Primary Insomnia: Three-week Treatment With Zolpidem Vs. Lorazepam
  28. In vivo methodology in behavioural pharmacology - where are we now?
  29. Possible Role of TGF – B Pathways in Schizophrenia / Moguća Uloga TTGF - B Signalnih Puteva U Shizofreniji
  30. Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze
  31. Depression correlates with sexual dysfunction and fatigue in multiple sclerosis patients
  32. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia
  33. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia
  34. P.8.b.006 Side effects of zolpidem and temazepam in treating primary insomnia
  35. Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response
  36. 2030 – Can TGF- β be a valuable marker for psychosis?
  37. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse
  38. Pharmacotherapeutical possibilities in mental disorders: Current status in Serbia
  39. P.5.c.001 Memantine improves poststroke cognitive impairment supported with mirtazapine
  40. PO18-WE-62 Seizures as predictive parameter in outcome of delirium tremens
  41. P.l.c.056 The most frequent used drugs at psychiatric clinical centre Kragujevac in 2007